Clearstead Trust LLC Has $942,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Clearstead Trust LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,716 shares of the biopharmaceutical company’s stock after selling 2,975 shares during the quarter. Clearstead Trust LLC’s holdings in Pfizer were worth $942,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Trifecta Capital Advisors LLC lifted its holdings in shares of Pfizer by 3.7% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 325 shares during the period. Confluence Wealth Services Inc. grew its stake in shares of Pfizer by 0.5% in the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares during the period. Carr Financial Group Corp raised its holdings in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its position in shares of Pfizer by 0.5% during the 3rd quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after buying an additional 364 shares during the period. Finally, Lafayette Investments Inc. boosted its stake in Pfizer by 2.2% in the 3rd quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 368 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.4 %

PFE stock traded up $0.11 during trading hours on Friday, reaching $27.81. 60,568,852 shares of the stock were exchanged, compared to its average volume of 41,900,304. The company has a market cap of $157.48 billion, a price-to-earnings ratio of -463.42, a PEG ratio of 1.18 and a beta of 0.63. The firm’s 50-day moving average is $26.88 and its 200-day moving average is $28.21. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the firm earned $1.23 EPS. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.36 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.